AMYRIS, INC.: management transactions · United States · SEC (Form 4)

About AMYRIS, INC.

AMYRIS, INC. is a U.S.-based industrial biotechnology company historically listed on the NASDAQ under the ticker AMRS. Founded in 2003 in the San Francisco Bay Area by scientists from the University of California, Berkeley, the company built its identity around a fermentation- and synthetic-biology platform marketed as “Lab-to-Market,” designed to convert renewable feedstocks into high-value ingredients and consumer products. Its corporate headquarters were long located in Emeryville, California, within its Bay Area R&D base. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1365916/000136591622000032/amrs-20211231.htm?utm_source=openai)) From a business-model perspective, Amyris has historically been organized around two main revenue streams. The first is sustainable ingredients for flavor and fragrance, nutrition, food and beverage, and beauty applications. The second is consumer products, particularly clean beauty, personal care, haircare, and health & wellness. The company has emphasized direct-to-consumer e-commerce and retail partnerships as key commercialization channels for its branded offerings. Its competitive edge has centered on its ability to engineer molecules through fermentation, scale selected ingredients industrially, and address demand for more sustainable alternatives to petrochemical- or animal-derived inputs. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1365916/000136591622000032/amrs-20211231.htm?utm_source=openai)) Geographically, Amyris developed an international footprint, with operations in North America and Brazil, where manufacturing and early labs were an important part of the strategy. It also relied on a network of manufacturing, logistics, and distribution partners. For investors, it is important to note that Amyris has had a highly uneven corporate history, characterized by heavy funding needs, restructuring activity, and significant operational complexity. The latest SEC filings and market references indicate that the company went through a major transformation phase, which had meaningful implications for its public-market status and visibility. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1365916/000136591622000032/amrs-20211231.htm?utm_source=openai)) In competitive terms, Amyris sits at the intersection of industrial biotech, specialty ingredients, and sustainability-led consumer products. Its value proposition is less that of a conventional pharmaceutical company and more that of a platform biotechnology business seeking to monetize intellectual property, differentiated ingredients, and consumer brands. The most recent material developments in the sources reviewed point primarily to restructuring and corporate transition rather than large-scale new product expansion. For equity investors, AMRS should therefore be viewed as a platform biotech case with a volatile historical profile, not as a mature consumer staples or healthcare incumbent. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1365916/000136591622000032/amrs-20211231.htm?utm_source=openai))